EGLN2 and Hodgkins lymphoma: Immunohistochemical studies described aberrant PHD1 expression in diverse malignancies (Couvelard et al. 2008; Gossage et al. 2010; Andersen et al. 2011; Kaufmann et al. 2013; Bur et al. 2018) and suggested a prognostic relevance of PHD1 expression in non-small cell type lung cancers (Andersen et al. 2011), pancreatic endocrine tumors (Couvelard et al. 2008), and classical Hodgkin's lymphoma (Bur et al. 2018).